A single dose of FCM without concomitant ESA therapy resulted in significantly increased Hb levels which were maintained for at least 8 weeks in this population of cancer patients with lymphoid malignancies, anemia, and functional iron deficiency receiving antineoplastic therapy. Here, GSTM1 is linked to anemia (phenotype).